Dr. Vitali Proutski has over 25 years of experience in cellular and molecular biology, research informatics, drug and diagnostics development. Before co-founding NBS Dr. Proutski was leading the efforts of AstraZeneca Pharmaceuticals (AZ) to establish a portfolio of collaborative R&D projects in Russia, ranging from pre-competitive research to drug co-development, as well as leading the Informatics function within the global R&D Information organization of AZ. Prior to that he was responsible for the Bioinformatics & Biostatistics Department of Almac Diagnostics (Business Unit of Almac Group Ltd - UK) as well as managed bioinformatics teams and technology development projects at Organon, a pharmaceutical company, in the UK and the Netherlands. While service as CEO of NBS, Vitali continued his scientific endeavors as Vice President, Informatics at Cambridge Epigenetics Ltd (UK), the leading epigenetics biomarker and technology development company. Vitali has dedicated his career to developing and applying novel informatics and genomics approaches to the discovery and development of medicines and diagnostics. One of the main focusses of Vitali's career has been the advancement of personalized medicine by means of discovering and developing reliable, clinically-relevant biomarkers and establishing robust biomarker discovery methodologies. Dr. Proutski has an Honors Degree (Cum Laude) from the 1st State Medical University, St. Petersburg and DPhil degree in computational biology from the University of Oxford, UK.

PhD in Biology. Oleg started his scientific career at the St. Petersburg Institute of Human Brain. He participated in the neurochemical laboratory development at the Oasi Maria Institute for Research on Mental Retardation and Brain Aging (Italy). Later, he worked at Emory University (USA) where he studied molecular mechanisms of the brain dopamine system. Oleg is the author of highly cited scientific works on the study of neurological and psychiatric syndrome autoimmune markers that was conducted in collaboration with Istituto Superiore di Sanita Institute (Rome, Italy). After his return to Russia, Oleg coordinated launching and further activity of the R&D division for new medication development at the Geropharm pharmaceutical company (Russia). Oleg is the author of numerous scientific works as well as domestic and international patents. He is also known as the developer of the BBB-ELISA-Test, a diagnostic kit registered in Russia that helps determine the degree of damage to the central nervous system in traumatic brain injuries. At the moment, Oleg works as the Managing Partner and Development Director at National BioService.